THEODORE B. SCHWARTZ, M.D., F.A.C.P.
It is only with some difficulty that even the older clinician can recall the days before the advent of tolbutamide for the treatment of maturity-onset diabetes. This is because tolbutamide, other sulfonylureas, and the biguanides have entrenched themselves as highly satisfactory therapeutic agents. Until 13 years ago the treatment of the adult-onset, obese diabetic often evolved into a battle between a concerned physician, who sternly offered the alternatives of prodigious weight loss and daily insulin injections, and a reluctant patient whose mood ranged from anxiety and hostility through desperation and despair. Despite early cautionary voices, the oral hypoglycemic agents were
SCHWARTZ TB. The Tolbutamide Controversy: A Personal Perspective. Ann Intern Med. ;75:303–306. doi: 10.7326/0003-4819-75-2-303
Download citation file:
Published: Ann Intern Med. 1971;75(2):303-306.
Endocrine and Metabolism, Hospital Medicine.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use